A study published today in Cell Reports reveals important insights into the molecular mechanisms that underpin the body's natural defenses against the development of skin cancer. The findings offer new clues into the behavior ...
Jan 11, 2022
0
72
Scientists from an international consortium led by Dr. Eduard Batlle, head of the Colorectal Cancer laboratory at IRB Barcelona, ICREA researcher and group leader of CIBER de Cáncer (CIBERONC), together with the Dutch company ...
Apr 25, 2022
0
68
Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anti-cancer drugs.
Nov 18, 2014
0
0
University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change ...
Jul 19, 2018
0
65
Patients with Merkel Cell Carcinoma who underwent a procedure called sentinel lymph node biopsy (SNLB) had a lower risk of cancer recurrence after two years, according to a study by researchers from Fox Chase Cancer Center. ...
Oct 3, 2011
0
0
Researchers at the Medical University of South Carolina (MUSC) have found a way to target drug-resistant esophageal cancer cells by exploiting the different energy needs of cancerous versus healthy cells. This breakthrough ...
May 21, 2019
0
188
Scientists at the Garvan Institute of Medical Research have identified molecular profiles of the surrounding matrix of a common type of lung cancer that might indicate which patients are likely to develop aggressive tumors.
Nov 20, 2022
1
402
Researchers at Fred Hutchinson Cancer Research Center have discovered a new drug target for squamous cell carcinoma – the second most common form of skin cancer. Scientists in the laboratory of Valeri Vasioukhin, Ph.D., ...
May 19, 2011
0
0
San Diego startup AltheaDx, which developed a molecular test designed to guide therapy for depression and anxiety based on a patient's genetics, is being acquired for $65 million in stock and cash.
Apr 7, 2022
0
3
A UT Southwestern researcher led a team that identified a new vulnerability in kidney tumors, the 10th most common cause of cancer death in men and women.
Jan 17, 2020
0
160
